Profile data is unavailable for this security.
About the company
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
- Revenue in USD (TTM)0.00
- Net income in USD-14.03m
- Incorporated2007
- Employees8.00
- LocationMinerva Neurosciences Inc1601 TRAPELO ROAD, SUITE 284WALTHAM 02451United StatesUSA
- Phone+1 (617) 600-7373
- Fax+1 (302) 636-5454
- Websitehttps://www.minervaneurosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cabaletta Bio Inc | 0.00 | -158.52m | 247.40m | 148.00 | -- | 1.77 | -- | -- | -2.51 | -2.51 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -80.43 | -40.80 | -97.39 | -43.86 | -- | -- | -- | -- | -- | -- | 0.1371 | -- | -- | -- | -71.21 | -- | 26.12 | -- |
| Sutro Biopharma Inc | 105.65m | -216.77m | 258.48m | 178.00 | -- | -- | -- | 2.45 | -25.98 | -25.98 | 12.61 | -10.25 | 0.3194 | -- | 19.98 | 340,793.60 | -65.54 | -31.36 | -94.60 | -37.63 | -- | -- | -205.18 | -152.29 | -- | -- | -- | -- | -59.64 | 7.74 | -112.99 | -- | -2.30 | -- |
| Shattuck Labs Inc | 1.00m | -54.90m | 258.81m | 44.00 | -- | 2.77 | -- | 258.81 | -1.02 | -1.02 | 0.0178 | 1.48 | 0.0094 | -- | -- | 22,727.27 | -51.77 | -32.04 | -56.50 | -35.04 | -- | -- | -5,489.50 | -721.60 | -- | -- | 0.00 | -- | 245.26 | -10.36 | 13.62 | -- | -33.97 | -- |
| Palisade Bio Inc | 0.00 | -11.23m | 259.27m | 8.00 | -- | 4.94 | -- | -- | -2.98 | -2.98 | 0.00 | 0.3522 | 0.00 | -- | -- | 0.00 | -137.67 | -130.84 | -221.20 | -165.85 | -- | -- | -- | -31,830.91 | -- | -1,041.55 | 0.0616 | -- | -100.00 | -- | -17.38 | -- | -- | -- |
| Avalo Therapeutics Inc | 192.00k | -99.70m | 260.22m | 23.00 | -- | 2.79 | -- | 1,355.33 | -8.79 | -8.79 | 0.0169 | 5.14 | 0.0017 | -- | -- | 8,347.83 | -89.35 | -94.60 | -128.95 | -128.31 | 54.69 | 81.11 | -52,019.79 | -790.66 | -- | -9.83 | 0.0248 | -- | -77.08 | -42.05 | -11.37 | -- | -- | -- |
| Crescent Biopharma Inc | 0.00 | -55.96m | 260.41m | 4.00 | -- | 1.17 | -- | -- | -21.97 | -21.97 | 0.00 | 8.40 | 0.00 | -- | -- | 0.00 | -72.70 | -55.66 | -86.54 | -62.83 | -- | -- | -- | -2,068.09 | -- | -- | 0.00 | -- | -100.00 | -- | -2.66 | -- | -41.45 | -- |
| Neurogene Inc | 0.00 | -85.13m | 261.62m | 107.00 | -- | 0.9398 | -- | -- | -4.12 | -4.12 | 0.00 | 17.97 | 0.00 | -- | -- | 0.00 | -37.67 | -27.58 | -40.40 | -29.44 | -- | -- | -- | -28,431.03 | -- | -- | 0.0001 | -- | -- | -- | -106.91 | -- | -1.67 | -- |
| Nautilus Biotechnology Inc | 0.00 | -62.81m | 272.82m | 124.00 | -- | 1.61 | -- | -- | -0.4982 | -0.4982 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -27.27 | -20.34 | -28.36 | -20.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.16 | -- | 18.04 | -- |
| Minerva Neurosciences Inc | 0.00 | -14.03m | 273.93m | 8.00 | -- | -- | -- | -- | -1.85 | -1.85 | 0.00 | -4.94 | 0.00 | -- | -- | 0.00 | -39.57 | -35.73 | -44.01 | -37.64 | -- | -- | -- | -263.85 | -- | -- | 2.36 | -- | -- | -- | 104.80 | -- | -- | -- |
| Aardvark Therapeutics Inc | 0.00 | -48.77m | 275.87m | 33.00 | -- | 2.25 | -- | -- | -2.53 | -2.53 | 0.00 | 5.63 | 0.00 | -- | -- | -- | -44.96 | -- | -47.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -185.63 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -132.00m | 277.52m | 65.00 | -- | 2.06 | -- | -- | -1.93 | -1.93 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -64.96 | -45.05 | -76.53 | -50.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -118.15 | -- | -7.58 | -- |
| Armata Pharmaceuticals Inc | 5.05m | -46.90m | 291.26m | 60.00 | -- | -- | -- | 57.63 | -1.30 | -1.30 | 0.1396 | -2.64 | 0.0538 | -- | 3.39 | 84,233.34 | -49.96 | -47.36 | -- | -60.79 | -- | -- | -928.00 | -829.99 | -- | -2.12 | 2.88 | -- | 14.24 | -- | 72.60 | -- | 53.02 | -- |
| Relmada Therapeutics Inc | 0.00 | -56.17m | 293.33m | 17.00 | -- | 14.03 | -- | -- | -1.80 | -1.80 | 0.00 | 0.2852 | 0.00 | -- | -- | 0.00 | -159.13 | -77.37 | -195.99 | -84.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.04 | -- | -- | -- |
| Prenetics Global Ltd | 66.32m | -40.67m | 301.86m | 285.00 | -- | 1.50 | -- | 4.55 | -3.10 | -3.54 | 5.01 | 14.26 | 0.3068 | 4.83 | 17.70 | 232,698.60 | -20.40 | -60.40 | -25.34 | -81.53 | 48.01 | 40.86 | -66.49 | -385.99 | 2.51 | -3.83 | 0.0129 | -- | 40.83 | 27.10 | 14.76 | -- | 23.29 | -- |
Data as of Feb 12 2026. Currency figures normalised to Minerva Neurosciences Inc's reporting currency: US Dollar USD
15.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 22 Dec 2025 | 3.57m | 8.24% |
| Farallon Capital Management LLCas of 22 Dec 2025 | 2.37m | 5.47% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 223.06k | 0.52% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 116.50k | 0.27% |
| Geode Capital Management LLCas of 30 Sep 2025 | 75.63k | 0.18% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 72.67k | 0.17% |
| Apella Capital LLCas of 31 Dec 2025 | 42.38k | 0.10% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 26.97k | 0.06% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 17.42k | 0.04% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 16.52k | 0.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
